Drug/Small Molecule:
oxytetracycline

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
Trade Names
  • Oxytetracycline HCl
  • Oxytetracycline anhydrous
  • Terramycin
Brand Mixture Names

PharmGKB Accession Id:
PA450757

Description

A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.

Source: Drug Bank

Indication

Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane.

Source: Drug Bank

Pharmacology

Oxytetracycline is known as a broad-spectrum antibiotic due to its activity against such a wide range of infections. It was the second of the tetracyclines to be discovered. Oxytetracycline, like other tetracyclines, is used to treat many infections common and rare. Its better absorption profile makes it preferable to tetracycline for moderately severe acne, but alternatives sould be sought if no improvement occurs by 3 months.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Absorption

Readily absorbed following oral administration.

Source: Drug Bank

Toxicity

Adverse effects may include stomach or bowel upsets and rarely allergic reactions. Very rarely severe headache and vision problems may be signs of dangerous intracranial hypertenion.

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H24N2O9

Source: Drug Bank

Isomeric SMILES

C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O

Source: OpenEye

Canonical SMILES

CN(C)[C@H]1[C@@H]

Source: Drug Bank

Average Molecular Weight

460.434

Source: Drug Bank

Monoisotopic Molecular Weight

460.148180376

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

No related genes are available.

Drug Interactions

Drug Description
oxytetracycline Increased risk of intracranial hypertension (source: Drug Bank)
oxytetracycline Increased risk of intracranial hypertension (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Formation of non-absorbable complexes (source: Drug Bank)
oxytetracycline Formation of non-absorbable complexes (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline The tetracycline increases the effect of digoxin in 10% of patients (source: Drug Bank)
oxytetracycline This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
oxytetracycline This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
oxytetracycline Increased risk of intracranial hypertension (source: Drug Bank)
oxytetracycline Increased risk of intracranial hypertension (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Tetracycline increases the risk of hypoglycemia (source: Drug Bank)
oxytetracycline Formation of non-absorbable complexes (source: Drug Bank)
oxytetracycline Increased risk of intracranial hypertension (source: Drug Bank)
oxytetracycline Formation of non-absorbable complexes (source: Drug Bank)
oxytetracycline Formation of non-absorbable complexes (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Possible antagonism of action (source: Drug Bank)
oxytetracycline Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline. (source: Drug Bank)
oxytetracycline Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided. (source: Drug Bank)

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0069-0730-66
DrugBank:
DB00595
ChEBI:
27701
KEGG Compound:
C06624
PubChem Compound:
5280972
PubChem Substance:
46507025
8850
Drugs Product Database (DPD):
719315
ChemSpider:
4444458
Therapeutic Targets Database:
DAP000401
FDA Drug Label at DailyMed:
6b4de8c9-8a32-4a07-9183-419d6177ea08

Clinical Trials

These are trials that mention oxytetracycline and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.